A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a single center, open label, 12-week study of inosine treatment. Inosine treatment
leads to an increase in the levels of urate (uric acid) in the blood.
The primary objective of the study is to determine the tolerability of oral administration of
inosine.
Secondary study objectives include the measurement of biomarkers of oxidative stress and
damage in response to inosine treatment.